750 related articles for article (PubMed ID: 25855895)
1. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
5. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
6. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
J Med Chem; 2016 Apr; 59(7):3018-33. PubMed ID: 26943020
[TBL] [Abstract][Full Text] [Related]
8. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
9. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Marighetti F; Steggemann K; Hanl M; Wiese M
ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Singh MS; Juvale K; Wiese M; Lamprecht A
Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
15. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
16. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
17. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
Stefan K; Schmitt SM; Wiese M
J Med Chem; 2017 Nov; 60(21):8758-8780. PubMed ID: 29016119
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
19. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]